Patient-derived xenograft (PDX) models in zebrafish larvae provides a unique humanized oncology drug discovery platform that mimics the complex tumor environment and pathophysiology of the patient. These models therefore increase the accuracy and translatability of the results and thereby reduce the risk of selecting non-viable lead drug candidates for further analysis.
Assess the inter-patient variability in drug efficacy and identify responding patient sub-groups using PDX-models
Design customized PDX trials together with Charles River Laboratory upon request or join BioReperia-hosted PDX-trials.
Predict anti-metastatic responses to commonly used anti-cancer drugs